Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in COVID-19 patients.
The DARE-19 trial involves dapagliflozin, which is marketed in the United States as Farxiga and can reduce blood glucose levels in diabetes patients. The double-blind trial follows previous research indicating that the drug also may provide some protection to the heart and kidney for high-risk patients. Patients with conditions like diabetes, heart disease and kidney disease are at higher risk of complications or death due to COVID-19.
The trial will involve 900 patients in the U.S. and globally, said Dr. Mikhail Kosiborod, a cardiologist with the Saint Luke's Mid America Heart Institute and principal investigator for the trial.
Read the full Kansas City Business Journal article: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications